Published in Ann N Y Acad Sci on July 01, 2011
The PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency. Am J Pathol (2013) 1.45
The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. J Natl Cancer Inst (2016) 0.94
Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. Hum Genomics (2013) 0.81
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice. Anat Physiol (2012) 0.77
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet (1999) 8.17
Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res (1997) 4.89
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene (2006) 3.27
A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J (2002) 3.05
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia (2002) 2.57
BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science (1999) 2.54
Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol (2009) 2.50
Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst (1998) 2.41
Cyclin D1 in breast cancer pathogenesis. J Clin Oncol (2005) 2.36
The mammalian ovary from genesis to revelation. Endocr Rev (2009) 2.31
Predicting response to endocrine therapy in human breast cancer: a hypothesis. Science (1975) 2.29
p53 and breast cancer, an update. Endocr Relat Cancer (2006) 2.27
Roles of BRCA1 and its interacting proteins. Bioessays (2000) 2.23
Li-Fraumeni syndrome--a molecular and clinical review. Br J Cancer (1997) 2.14
Hormone action in the mammary gland. Cold Spring Harb Perspect Biol (2010) 2.10
Conditional gene expression in secretory tissues and skin of transgenic mice using the MMTV-LTR and the tetracycline responsive system. J Cell Biochem (1995) 1.93
History of aromatase: saga of an important biological mediator and therapeutic target. Endocr Rev (2009) 1.88
Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol (2005) 1.82
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene (2001) 1.82
Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science (1996) 1.82
Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. J Natl Cancer Inst (1998) 1.77
Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev (2009) 1.69
Post-translational regulation of the tumor suppressor p27(KIP1). Cell Mol Life Sci (2008) 1.68
Dynamics of nuclear receptor target gene regulation. Chromosoma (2010) 1.63
Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol (2010) 1.63
The epidemiology of breast cancer. CA Cancer J Clin (1991) 1.62
Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer (2004) 1.60
Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol Reprod (1996) 1.57
The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol (2005) 1.52
Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr (2000) 1.50
Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia (2004) 1.47
Deregulated estrogen receptor alpha expression in mammary epithelial cells of transgenic mice results in the development of ductal carcinoma in situ. Cancer Res (2005) 1.46
Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett (2005) 1.44
BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol (2004) 1.43
BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol (2009) 1.43
Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma. Carcinogenesis (1997) 1.41
Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. Cancer Res (2005) 1.37
p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res (2002) 1.36
Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene (1991) 1.36
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat (2001) 1.34
The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application. Endocr Relat Cancer (2003) 1.32
The endocrine system and ageing. J Pathol (2007) 1.31
Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids (2008) 1.30
Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated? Endocr Relat Cancer (2009) 1.30
Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest (2007) 1.24
Rat strain-specific actions of 17beta-estradiol in the mammary gland: correlation between estrogen-induced lobuloalveolar hyperplasia and susceptibility to estrogen-induced mammary cancers. Proc Natl Acad Sci U S A (2000) 1.24
Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERalpha-negative and ERalpha-positive mammary preneoplasia and cancer. Oncogene (2007) 1.24
Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene (2005) 1.19
p53 suppresses Src-induced podosome and rosette formation and cellular invasiveness through the upregulation of caldesmon. Mol Cell Biol (2009) 1.19
Hormone dependence in premalignant mammary progression. Cancer Res (2003) 1.16
The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat (1994) 1.15
Structural determinants of the BRCA1 : estrogen receptor interaction. Oncogene (2005) 1.15
Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol (2007) 1.13
Estrogen signaling via estrogen receptor {beta}. J Biol Chem (2010) 1.12
A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. Oncogene (2007) 1.10
RSK in tumorigenesis: connections to steroid signaling. Steroids (2010) 1.08
An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J Biol Chem (2001) 1.07
BRCA1 in hormonal carcinogenesis: basic and clinical research. Endocr Relat Cancer (2005) 1.04
Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol (2010) 1.04
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene (2004) 1.03
Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma. Am J Pathol (2003) 1.03
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. Oncogene (2008) 1.02
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int (2001) 0.99
ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab (2010) 0.98
Genetic determination of susceptibility to estrogen-induced mammary cancer in the ACI rat: mapping of Emca1 and Emca2 to chromosomes 5 and 18. Genetics (2004) 0.98
Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res (2010) 0.97
Estrogen and progesterone induce persistent increases in p53-dependent apoptosis and suppress mammary tumors in BALB/c-Trp53+/- mice. Breast Cancer Res (2008) 0.97
Regulation of aromatase expression in breast cancer tissue. Ann N Y Acad Sci (2009) 0.97
The role of SRC-3 in human breast cancer. Nat Rev Clin Oncol (2009) 0.95
Chemoprevention of breast cancer. Breast Cancer Res Treat (2000) 0.95
The complex relationship between BRCA1 and ERalpha in hereditary breast cancer. Clin Cancer Res (2009) 0.95
Developing a mammary gland is a stat affair. J Mammary Gland Biol Neoplasia (1997) 0.94
Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: clinical implications. Clin Cancer Res (2005) 0.94
Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis (2010) 0.94
Cell proliferation regulated by estradiol receptor: Therapeutic implications. Steroids (2009) 0.93
Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Mol Endocrinol (2011) 0.92
Estrogens, regulation of p53 and breast cancer risk: a balancing act. Cell Mol Life Sci (2010) 0.92
Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. Oncol Rep (2005) 0.91
Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res (2010) 0.90
Conditional over-expression of estrogen receptor alpha in a transgenic mouse model. Transgenic Res (2002) 0.90
Cancer development and its natural history. A cancer prevention perspective. Cancer (1988) 0.90
BRCA1, hormone, and tissue-specific tumor suppression. Int J Biol Sci (2008) 0.89
Ubiquitin-like protein modifications in prostate and breast cancer. Front Biosci (2007) 0.88
Tamoxifen induces regression of estradiol-induced mammary cancer in the ACI.COP-Ept2 rat model. Breast Cancer Res Treat (2008) 0.88
Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology (2005) 0.87
Conditional control of gene expression in the mammary gland. J Mammary Gland Biol Neoplasia (1997) 0.87
BRCA1 in hormone-responsive cancers. Trends Endocrinol Metab (2003) 0.85
BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Dis (2010) 0.85
Human breast cell proliferation and its relationship to steroid receptor expression. Climacteric (2004) 0.84
Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol (2008) 0.84
Possible role of Stat5a in rat mammary gland carcinogenesis. Breast Cancer Res Treat (2004) 0.82
Loss of cyclin D1 in concert with deregulated estrogen receptor alpha expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene (2007) 0.82
Loss of protein phosphatase 2A expression correlates with phosphorylation of DP-1 and reversal of dysplasia through differentiation in a conditional mouse model of cancer progression. Cancer Res (2003) 0.82
Gene expression profiles of the oestrogen receptor in breast cancer. Neth J Med (2010) 0.79
Real-time imaging and characterization of human breast tissue by reflectance confocal microscopy. J Biomed Opt (2007) 1.17
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res (2011) 1.01
Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol (2005) 0.99
Aromatase and COX in breast cancer: enzyme inhibitors and beyond. J Steroid Biochem Mol Biol (2007) 0.94
Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Mol Endocrinol (2011) 0.92
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
The role of calcium in the activation of estrogen receptor-alpha. Cancer Res (2011) 0.83
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem (2005) 0.81
Time-lapse imaging of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer. J Vis Exp (2013) 0.80
The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cancer Prev Res (Phila) (2012) 0.79
Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.79
Activated stress response pathways within multicellular aggregates utilize an autocrine component. Cell Signal (2006) 0.78
Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations. Ann N Y Acad Sci (2012) 0.76
Long term metabolic arrest and recovery of HEK293 spheroids involves NF-kappaB signaling and sustained JNK activation. J Cell Physiol (2006) 0.76